{"id":703379,"date":"2024-06-20T13:12:01","date_gmt":"2024-06-20T13:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=703379"},"modified":"2024-06-20T13:12:01","modified_gmt":"2024-06-20T13:12:01","slug":"ibogaine-by-david-dardashti-expands-software-capabilities-with-advanced-statistical-modeling-for-precision-ibogaine-dosing","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ibogaine-by-david-dardashti-expands-software-capabilities-with-advanced-statistical-modeling-for-precision-ibogaine-dosing_703379.html","title":{"rendered":"Ibogaine By David Dardashti Expands Software Capabilities with Advanced Statistical Modeling for Precision Ibogaine Dosing"},"content":{"rendered":"
\"Ibogaine<\/a><\/div>\n
Ibogaine By David Dardashti, a leading innovator in ibogaine therapy, today announced a significant advancement in its proprietary software platform designed to optimize treatment outcomes for addiction, depression, and trauma. The new module incorporates engineering statistics to enhance personalized dosing, adapt to individual patient variability, and further refine treatment protocols.<\/div>\n

Engineering Statistics for Personalized Medicine<\/strong><\/p>\n

The enhanced software leverages descriptive statistics and control charts to analyze patient data and establish individualized ibogaine dosage ranges. By calculating the mean and standard deviation of ibogaine doses for different patient subgroups, the software determines a dosing range that falls within two standard deviations of the mean, ensuring the majority of patients are covered while accounting for individual variations.<\/p>\n

Adaptive Dosing Through Continuous Monitoring<\/strong><\/p>\n

The software’s control charts continuously monitor dosing trends, enabling clinicians to quickly detect any significant shifts in optimal dosage caused by new factors. This real-time feedback loop allows for rapid adjustments to treatment plans, ensuring patients receive the most effective and safe dose of ibogaine.<\/p>\n

T-Tests for Comparative Analysis<\/strong><\/p>\n

To further refine treatment protocols, the software employs t-tests to compare the effectiveness of ibogaine in patients struggling with addiction versus those solely battling mental health issues. This rigorous statistical analysis helps clinicians understand the nuances of ibogaine’s therapeutic effects and tailor treatment plans accordingly.<\/p>\n

Commitment to Research and Innovation<\/strong><\/p>\n

“This latest advancement in our software platform underscores our commitment to advancing the field of ibogaine therapy through research and innovation,” said David Dardashti, CEO of Ibogaine By David Dardashti. “By incorporating engineering statistics into our dosing algorithms, we are taking a significant step towards personalized medicine and ensuring the highest level of care for our patients.”<\/p>\n

About Ibogaine By David Dardashti<\/strong><\/p>\n

Ibogaine By David Dardashti is a leading provider of innovative ibogaine treatment solutions. We are dedicated to advancing the field of ibogaine therapy through research, education, and cutting-edge technology. Our mission is to make ibogaine treatment accessible to all who need it and to help individuals overcome addiction, trauma, and depression to achieve lasting healing.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Ibogaine By David Dardashti<\/a>
Contact Person:<\/strong> Cole Barressi
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> www.ibogaineclinic.com<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Ibogaine By David Dardashti, a leading innovator in ibogaine therapy, today announced a significant advancement in its proprietary software platform designed to optimize treatment outcomes for addiction, depression, and trauma. The new module incorporates engineering statistics to enhance personalized dosing, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[421,447,405,420,411],"tags":[],"class_list":["post-703379","post","type-post","status-publish","format-standard","hentry","category-Computers-Software","category-Education","category-Health-Medicine","category-Science","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=703379"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703379\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=703379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=703379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=703379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}